GAYLA CRAGG: Open Payments
NPI 1730728098 · WILMINGTON, DE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$622 in 7 payments from 6 companies in 2025. Trend: 2023 $84 · 2024 $0 · 2025 $622
Food & beverage: $622
| Company | Payments | Amount |
|---|---|---|
| Alkermes, Inc. | 2 | $187 |
| Xeris Pharmaceuticals, Inc. | 1 | $122 |
| Janssen Pharmaceuticals, Inc | 1 | $117 |
| Teva Pharmaceuticals USA, Inc. | 1 | $100 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $62 |
| E.R. Squibb & Sons, L.L.C. | 1 | $35 |
Products named: RECORLEV, SPRAVATO, ARISTADA, AUSTEDO XR, LYBALVI, CAPLYTA, COBENFY.
Industry payments across DE — which companies pay providers there.
